key: cord-258584-qy3tg4ow
authors: Christopeit, Maximilian; Schmidt-Hieber, Martin; Sprute, Rosanne; Buchheidt, Dieter; Hentrich, Marcus; Karthaus, Meinolf; Penack, Olaf; Ruhnke, Markus; Weissinger, Florian; Cornely, Oliver A.; Maschmeyer, Georg
title: Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
date: 2020-10-20
journal: Ann Hematol
DOI: 10.1007/s00277-020-04297-8
sha: 
doc_id: 258584
cord_uid: qy3tg4ow

To ensure the safety of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT), evidence-based recommendations on infectious complications after HDC/ASCT are given. This guideline not only focuses on patients with haematological malignancies but also addresses the specifics of HDC/ASCT patients with solid tumours or autoimmune disorders. In addition to HBV and HCV, HEV screening is nowadays mandatory prior to ASCT. For patients with HBs antigen and/or anti-HBc antibody positivity, HBV nucleic acid testing is strongly recommended for 6 months after HDC/ASCT or for the duration of a respective maintenance therapy. Prevention of VZV reactivation by vaccination is strongly recommended. Cotrimoxazole for the prevention of Pneumocystis jirovecii is supported. Invasive fungal diseases are less frequent after HDC/ASCT, therefore, primary systemic antifungal prophylaxis is not recommended. Data do not support a benefit of protective room ventilation e.g. HEPA filtration. Thus, AGIHO only supports this technique with marginal strength. Fluoroquinolone prophylaxis is recommended to prevent bacterial infections, although a survival advantage has not been demonstrated.

High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) constitute a standard of care in the treatment of heamatologic malignancies, in particular, multiple myeloma [1] , malignant lymphoma [2, 3] and acute myeloid leukaemia [4] . HDC and ASCT are also used in solid tumours such as neuroblastoma, sarcoma, germinal tumours [5] and autoimmune diseases e.g. multiple sclerosis [6], systemic sclerosis [7] and Crohn's disease [8] . In total, the number of ASCT reported to the European Society for Blood and Marrow Transplantation in 2018 exceeds 27,750, including more than 560 for non-malignant disorders, mostly autoimmune diseases, and 1545 for solid tumours [9] .

After HDC and ASCT, up to 90% of patients will experience infections, mostly presenting as fever of unknown origin (FUO) [10] .

Due to indwelling venous catheters and toxicities of conditioning regimens, in particular, mucositis and gastrointestinal barrier impairment, both Gram-positive and Gramnegative bacteria may cause fever and infection after HDC/ ASCT [11] . Bacterial pneumonia, colitis and bloodstream infection (BSI), including catheter-related BSI, are the prevailing documented infections in patients after HDC/ASCT [11, 12] . Invasive fungal disease and viral infections, ranging from herpes to hepatitis viruses, may occur as well, extending into the period after transplantation [13, 14] .

These recommendations on prophylaxis, diagnosis and treatment of infectious complications after HDC/ASCT by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) are the fourth edition after 1999, 2003 and 2012 [15] [16] [17] . The expert panel assessed the recommendations in a stepwise consensus process, consisting of telephone and video conferences. All members of the AGIHO were invited to the consensus meetings. The guideline was approved by the AGIHO assembly on May 7, 2020.

This guidance document is embedded into other AGIHO recommendations on infection management in patients with haematological and oncological diseases [18] [19] [20] [21] [22] [23] [24] [25] . It provides an evaluation of current evidence and the consensus interpretation of the authors. Recommendations are not mandatory and intend to assist physicians in decisions on individual patients. We regard correct dosing to be a responsibility of the prescribing physicians and do not mention this in this guideline.

Strength of recommendation and quality of evidence were graded according to the criteria applied by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM ; Table 1 ) [26, 27] . 

Both depth and duration of neutropenia have been associated with the risk of cancer patients to develop an infection that will take a more severe and complicated course [28] . AGIHO regards patients with expected neutropenia < 500/μl for at least 8 days to be at high risk and those with an expected duration of neutropenia of up to 7 days at standard risk for the development of an infection with a complicated course [18] . While it is generally presumed that patients after HDC/ASCT are amongst those with neutropenia lasting for 8 days or longer, thus are at high risk for complicated infection, data from prospective clinical trials show that the duration of neutropenia may often be in the standard risk range after HDC/ ASCT [29] . However, profound, and sometimes longlasting defects of components of the adaptive immune system are observed besides neutropenia after HDC/ ASCT. Causes may lie in the nature of the underlying disease, timing and type of previous treatments, history of previous infection and specifics of the conditioning regimen e.g. nucleoside analogues or antilymphocyte globulins [6, [30] [31] [32] [33] [34] . In conclusion, AGIHO considers patients after HDC/ASCT at high risk for developing infections with a complicated course. Hereby, conditioning with carmustine, etoposide, cytarabine and melphalan (BEAM) prior to ASCT is associated with an increased risk for infections compared to conditioning with highdose melphalan [35] .

Diagnostic procedures before the onset of fever or infection Surveillance blood cultures in the absence of fever or other signs of infection are discouraged [36, 37] . Likewise, routine screening for invasive aspergillosis by serial determination of galactomannan antigen or 1,3-β-D-glucan is not recommended in these patients [38] . In individual patients at increased risk for invasive Aspergillus spp. infection, e.g. patients with previous aspergillosis who are without current systemic mould-active prophylaxis, twice-weekly galactomannan and/ or 1,3-β-D-glucan surveillance may be considered. For more detailed information, refer to the separate guideline on diagnosis of fungal infection [20] . Screening for hepatitis B virus (HBV; anti-HBc antibodies, HBsAg, nucleic acid testing), hepatitis C virus (HCV; anti-HCV, nucleic acid testing), hepatitis E virus (HEV; nucleic acid testing) and human immunodeficiency virus (HIV; HIV1/2 antibodies, nucleic acid testing) is requested in all patients prior to release of the autologous graft [39, 40] . These screening tests should be repeated at least 30 days before HDC/ASCT. Monitoring of HBV viral load is strongly recommended in HBsAg and/or anti-HBc antibody positive patients for 6 months after HDC/ASCT, as immunosuppression can lead to viral reactivation and disease [41] [42] [43] [44] [45] . If maintenance therapy using rituximab, lenalidomide or bortezomib is administered, monitoring should be continued for 6 months following cessation of the respective maintenance therapy.

In patients with respiratory symptoms, screening for respiratory tract pathogens should include severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). HDC/ASCT may be deferred until the patient is asymptomatic [46, 47] .

Diagnostic procedures recommended before onset of fever or infection are given in Table 2 .

Thorough physical examination of a febrile neutropenic patient is mandatory. We strongly recommend two separate pairs of venous blood cultures in case of fever or other signs or symptoms of infection. In the presence of a central venous catheter (CVC), one of the two pairs should be obtained from the catheter. To increase the diagnostic yield of blood cultures, it is recommended with moderate strength to draw blood from each individual CVC lumen, or to obtain a third pair of blood cultures [48] [49] [50] . Determination of the differential time to positivity (DTTP) between blood cultures drawn from the CVC and a peripheral vein might be useful to identify the source of BSI [51] . DTTP of 2 h or more is suggestive of catheter-related BSI [52] . DTTP may be a useful tool to diagnose Candida spp. BSI, with a cut-off value of 6 h for Candida glabrata BSI and 2 h for other Candida spp. [53] . In contrast, DTTP has not proven useful in the diagnosis of Staphylococcus aureus BSI [54, 55] . In S. aureus or Candida spp. BSI CVC should be removed whenever possible, independent of the exact source of infection [24] . Chest X-rays are commonly discouraged to diagnose lung infection in tumour patients, since infiltrates are frequently invisible [56, 57] . High-resolution/multislice thoracic CT scan without contrast enhancement has a significantly higher sensitivity than chest X-ray and should be performed in patients with respiratory symptoms or persisting fever despite antimicrobial treatment over 72-96 h [22, 57] . Diagnostic bronchoscopy, bronchial or bronchoalveolar lavage for patients with pulmonary infiltrates (histology, cytology, culture, antigen testing, nucleic acid testing) should be applied whenever possible. Further diagnostics (e.g. abdominal or central nervous system imaging) might also be required, depending on symptoms, clinical signs and laboratory parameters. Signs of sepsis in the absence of fever as well as hypothermia should prompt diagnostic procedures as for a first fever, and empiric antibiotic treatment.

Diagnostic procedures recommended at onset of fever or infection are summarized in Table 3 . [110] Antimicrobial prophylaxis for patients during and after HDC/ASCT

Prophylactic antimicrobial use can be considered in ASCT recipients during pre-engraftment when the duration of profound neutropenia (absolute neutrophil count < 100/μl) is expected to be at least 7 days. One placebo-controlled randomized trial has shown a reduction in the number of infections in patients, including those after HDC/ASCT, when using levofloxacin prophylaxis [58] . Moreover, a retrospective study with ASCT recipients has shown significant reduction of febrile neutropenia and BSI under prophylaxis with [114] levofloxacin [10] . Of note, levofloxacin is not approved for antibacterial prophylaxis in Germany. An increasingly critical view of fluoroquinolone prophylaxis is explained by the absence of a survival benefit of fluoroquinolone prophylaxis in randomized clinical trials as well as by toxicities associated with fluoroquinolone use [58, 59] . Fluoroquinolone-resistant Enterobacteriaceae have been linked to community fluoroquinolone consumption. Prophylactic efficacy is reduced in neutropenic patients when the prevalence of fluoroquinolone resistance exceeds 20% in Gram-negative bacteria [60] .

In summary, AGIHO recommends to critically weigh expected benefits of fluoroquinolone prophylaxis against the risks and consider local bacterial epidemiology and individual patient risk factors for fatal outcome of infections. AGIHO strongly recommends fluoroquinolone prophylaxis if the intention is to prevent bacterial infection. It cannot be expected to reduce risk of death with such prophylaxis [58] .

Clostridioides difficile enteritis occurred in 3% vs. 8% after HDC/ASCT in a randomized comparison of fidaxomicin versus placebo [61] . Since the incidence of C. difficile-associated diarrhoea was low in both the placebo and in the fidaxomicin arm, AGIHO does not recommend prophylaxis of C. difficile enteritis after HDC/ASCT in the clinical routine.

Available data do not support the prophylactic use of antifungals to prevent invasive fungal disease (IFD). Those are rare events after HDC/ASCT and no reduction in mortality has been found in patients after HDC/ASCT [62, 63] . This is particularly true for mould-active antifungal agents. Yet, antifungal prophylaxis might be considered on a case-by-case basis if severe and long-lasting immunosuppression is expected.

The value of protective room ventilation such as highefficiency particulate air (HEPA) filtration, positive pressure-directed airflow or laminar airflow is not well established for HDC/ASCT patients. During the last two decades, the use of air-filtered rooms has decreased as the incidence of filamentous fungal infections is extremely low in patients undergoing HDC/ASCT [64] . In a prospective clinical trial with 400 HDC/ASCT patients from nine transplant centres, no significant impact of HEPA filtration on the incidence of pneumonia, including IFD, or mortality rate was observed [65] . Thus, there are no data to mandate air-filtered rooms and AGIHO supports a recommendation of air-filtered rooms with marginal strength.

Prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is efficacious with trimethoprim/sulfamethoxazole (TMP/SMX). A meta-analysis calculated an RR of 0.15 (95% CI 0.04-0.62) for an HIV-negative immunosuppressed individual to experience PJP when receiving prophylaxis with TMP/SMX, with a reduction of P. jirovecii-related mortality but no effect on all-cause mortality [66] . Reflecting mostly low quality of evidence due to bias and imprecision, AGIHO moderately supports a recommendation of TMP/ SMX to prevent PJP after HDC/ASCT. If the administration of TMP/SMX is not feasible, alternatives are atovaquone, or pentamidine administered by inhalation or intravenously. These alternatives have not been studied in the HDC/ASCT setting and recommendations are transferred from other populations. The duration of P. jirovecii-directed prophylaxis should last for at least 3 months, preferably until the CD4+ T cell count stably exceeds 200/μl.

There are no large randomized controlled trials that evaluate antiviral drugs to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) disease after HDC/ASCT. Newer studies-including recently published placebocontrolled vaccination trials-showed that HSV infection, in particular, gingivostomatitis, and herpes zoster are still of concern in these patients [67] [68] [69] . Noteworthy, herpes zoster also frequently occurred beyond 6 months post-transplant, particularly in unvaccinated patients [69] . Antiviral drug use was reported in~90% in this trial, with a duration of > 6 months iñ 40% [69] . Several studies, including placebo-controlled studies and meta-analyses (but not focused on ASCT patients) showed that acyclovir is useful to prevent and treat HSV and VZV diseases [70, 71] . Thus, we strongly recommend acyclovir prophylaxis for at least 6 months, in particular, if CD34selected grafts are used [34, 72] . Inactivated VZV vaccine is strongly recommended for all seropositive HDC/ASCT patients [69] .

Cytomegalovirus (CMV) infection (reactivation) has been reported in some patients of mainly retrospective analyses focused to patients with fever after HDC/ASCT [73, 74] . However, CMV disease, i.e. organ involvement, is very rare in this setting [74] . In summary, CMV is no major concern in patients after HDC/ASCT. AGIHO supports a recommendation against the use of CMV prophylaxis.

Human herpes virus 6 (HHV-6) and Epstein-Barr virus (EBV) infections are infrequent after HDC/ASCT and routine prophylaxis is not recommended [75, 76] . However, EBV reactivation has been reported at a high frequency in patients with multiple sclerosis undergoing ASCT [77] . Thus, nucleic acid-based screening for EBV viremia at follow-up presentations and preemptive treatment with rituximab in the case of EBV infection should be considered in these patients.

Reactivation of viral hepatitis in patients after HDC/ASCT with previous or ongoing chronic HBV infection i.e. HBsAg and/or anti-HBc positivity is associated with considerable morbidity and mortality. Reactivation has long been prevented using lamivudine. Lamivudine resistance can reach more than 70% in primary treatment of viral hepatitis B after long-time therapy [78] . Here, viral clearance and HBeAg status, amongst others, are important risk factors for the development of resistance. Today, tenofovir and entecavir are antiviral substances with resistance rates of 1-5%. Their prophylactic administration is safe even in combination with most of the conditioning regimens [79, 80] . AGIHO strongly recommends the use of either tenofovir or entecavir in patients with HBsAg-and/or anti-HBc positivity. Patients should regularly be monitored for reactivation despite antiviral prophylaxis by HBV DNA measurements. In addition to patients after HDC/ ASCT, patients under steroid medication and patients after the use of anti-CD20-antibodies, e.g. during maintenance therapy after HDC/ASCT, are at high risk for HBV reactivation [81] .

Notably, the presence of anti-HBc IgM indicates acute infection and should trigger HBV DNA PCR. In acute HBV infection, clinical priority will frequently be to treat hepatitis before continuing antineoplastic treatment. For negative HBV DNA PCR, a combination of HBsAg negativity, anti-HBc positivity, anti-HBs negativity most frequently is a sign of resolved infection. As it can also mirror low-level chronic infection or resolving acute infection, AGIHO recommends repeating such test to rule out a false-positive result for anti-HBc. Likewise, virustatic prophylaxis as outlined before and close monitoring of HBV DNA load is recommended if this specific constellation is repeatedly documented.

AGIHO as well as the German standing committee on vaccination recently published separate guidelines on antiinfective vaccination measures against vaccine-preventable diseases with an own section on the situation after HDC/ ASCT [82, 83] .

Recommendations on antimicrobial prophylaxis are summarized in Table 4 . [126] Empiric antimicrobial therapy of fever of unknown origin Empiric treatment of FUO during neutropenia after HDC/ ASCT should follow recently published guidelines on the management of high-risk febrile neutropenia [18] . In summary, AGIHO strongly recommends to use single-agent broadspectrum Pseudomonas-active antibiotics such as piperacillin/ tazobactam, ceftazidime, cefepime, meropenem or imipenem/ cilastatin as first line antibiotic therapy [18, 84] . As there is no systematic data on the empiric use of doripenem [85] , ceftazidime-avibactam [86] , ceftolozane-tazobactam [87] or cefozopran [88] in this setting, they are not discussed here.

The upfront routine addition of tigecycline to first-line betalactam with anti-pseudomonal activity did not reduce the mortality rate and is therefore not recommended outside settings of high-level multidrug resistance [84] . Upfront addition of antibiotics with activity against Gram-positive bacteria such as glycopeptides (e.g. vancomycin, teicoplanin) [89] , oxazolidinones (e.g. linezolid) or cyclic lipopeptides (e.g. daptomycin) has either shown no benefit or has not been studied properly, thus, we do not recommend their use. In patients with known colonization by VRE, addition of linezolid was not beneficial [90, 91] . The administration of antimicrobial agents active against MRSA or ESBL-producing Gram-negative bacteria is recommended with marginal strength in case of colonization with these pathogens. The addition of an aminoglycoside in clinically stable patients in first-line therapy is not recommended [92] [93] [94] . However, in case of clinical instability, their addition is moderately recommended as might the addition of glycopeptides. Changing the first-line antibiotic regimen in a clinically stable patient who is still febrile after > 96 h is not generally recommended [18, 95, 96] . Empiric use of antifungals during first-line therapy in a clinically stable patient with FUO after HDC/ASCT is not recommended [97] [98] [99] . However, second-line addition of a mould-active antifungal is recommended with marginal strength for patients with persisting fever for at least 96 h receiving a broad-spectrum first-line antibacterial therapy who had not received prior antifungal prophylaxis and [133] who are expected to experience neutropenia for more than 7 days [97] [98] [99] . This is not recommended if a mouldactive antifungal prophylaxis had been administered prior to signs of infection or fever. For second-line empiric a n t i f u n g a l t h e r a p y , c a s p o f u n g i n o r l i p o s o m a l amphotericin B are preferred, while conventional amphotericin B deoxycholate is not recommended due to an unfavourable toxicity profile.

Recommendations on empiric antimicrobial therapy are summarized in Table 5 .

Recommendations on management of pulmonary infiltrates [22] , gastrointestinal and perineal infections [23] , central nervous system infection [25] , central venous catheter-related infection [24] and invasive fungal infections [21] can be found in the respective guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO). Georg Maschmeyer reports personal fees from Gilead, Merck-Serono, Astra Zeneca and AMGEN and personal fees and non-financial support from Janssen Cilag, outside the submitted work.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma

Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

Association between CMV and invasive fungal infections after autologous stem cell transplant in lymphoproliferative malignancies: opportunistic partnership or cause-effect relationship?

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients

Interventional antimicrobial therapy for febrile complications after high-dose chemotherapy and autologous stem cell transplantation. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology

Antimicrobial therapy of febrile complications after high-dose chemo−/radiotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO)

Treatment of invasive fungal diseases in cancer patients -Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology

CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation) -Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Infectious complications of acute leukemia

Bortezomib and highdose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre singlegroup phase 2 trial

T cell repertoire following autologous stem cell transplantation for multiple sclerosis

Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma

Utility of surveillance blood cultures in patients undergoing hematopoietic stem cell transplantation

Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center

What is the role of the (1->3)-beta-D-glucan assay in the screening of patients undergoing autologous haematopoietic stemcell transplantation?

Blood-borne hepatitis E virus transmission: a relevant risk for immunosuppressed patients

Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen -Erste Fortschreibung

High risk of hepatitis B reactivation among patients with acute myeloid leukemia

HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea

Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: a multicenter study

Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study

Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis from an endemic area

Community acquired respiratory virus infections in cancer patients-guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology

Frequently asked questions regarding SARS-CoV-2 in cancer patientsrecommendations for clinicians caring for patients with malignant diseases

Detection of bloodstream infections in adults: how many blood cultures are needed?

Optimal testing parameters for blood cultures

How many lumens should be cultured in the conservative diagnosis of catheter-related bloodstream infections?

Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis

Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures

Diagnostic usefulness of differential time to positivity for catheter-related candidemia

Differential time to positivity is not predictive for central linerelated Staphylococcus aureus bloodstream infection in routine clinical care

Differential time to positivity of central and peripheral blood cultures is inaccurate for the diagnosis of Staphylococcus aureus long-term catheter-related sepsis

Chest low-dose computed tomography in neutropenic acute myeloid leukaemia patients

Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography

Gruppo Italiano Malattie Ematologiche dell'Adulto Infection P (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients

A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation

Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group

National Institute of A, Infectious Diseases Mycoses Study G (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

The availability of HEPAfiltered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study

Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients

Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial

Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebocontrolled trial (ZOE-HSCT)

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, doubleblind, placebo-controlled trial

Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation

Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials

Virus reactivation in high-risk non-Hodgkin's lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation

Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab

Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant

Human herpesvirus 6 infection after autologous stem cell transplantation: a multicenter prospective study in adult patients

Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay

Epstein-Barr virus and monoclonal gammopathy of clinical significance in autologous stem cell transplantation for multiple sclerosis

EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy

Tenofovir for the treatment of hepatitis B virus

Characteristics, prevention, and management of hepatitis B virus (HBV) reactivation in HBV-infected patients who require immunosuppressive therapy

Antiinfective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in highrisk hematologic patients with cancer with febrile neutropenia

A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study

Antimicrobial activities of ceftazidime-avibactam and comparator agents against clinical bacteria isolated from patients with cancer

Use of ceftolozane/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient

Japan Febrile Neutropenia Study G (2015) Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: a multicenter prospective randomized trial

Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials

Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycinresistant Enterococcus spp

Impact of empiric treatment for vancomycin-resistant Enterococcus in colonized patients early after allogeneic hematopoietic stem cell transplantation

Gruppo Italiano Malattie Ematologiche dell'Adulto Infection P (2001) A multicenter, double-blind, placebocontrolled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis

Beta-lactam versus betalactam-aminoglycoside combination therapy in cancer patients with neutropenia

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america

International Antimicrobial Therapy Group of the European Organization for Research Treatment of C (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial

Metaanalysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with highrisk febrile neutropenia

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study

Hepatitis E virus infection in an Italian cohort of hematopoietic stem cell transplantation recipients: seroprevalence and infection

Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant

Is cytomegalovirus surveillance necessary for patients with low reactivation risk in an autologous hematopoietic cell transplantation setting?

Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation

Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study

Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy

Monitoring human herpesvirus-6 in patients with autologous stem cell transplantation

Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis

How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal

Evaluation of the usefulness of a quantitative blood culture in the diagnosis of catheterrelated bloodstream infection: comparative analysis of two periods

Individual versus pooled multiple-lumen blood cultures for the diagnosis of intravascular catheter-related infections

Sorveglianza Epidemiologica Infezioni nelle Emopatie G (2019) A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: a prospective multicenter study of the SEIFEM group

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology

Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study

Protective isolation in hemopoietic stem cell transplants: a review of the literature and single institution experience

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer

Zoster-039 s g (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies

Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis

Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation

Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation

Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy

Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial

Comparison of antipseudomonal beta-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis

Piperacillin/ tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies

Is i (2013) Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations